Evidence map›Paper›PMID 17116668›Full record

ArticleAntimicrobial agents and chemotherapy2007

Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Daniel E Rozen, Lesley McGee, Bruce R Levin, Keith P Klugman

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. mBio · 2024
    Article
  6. Article
  7. Article
  8. Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  9. The cost of evolved constitutiveEcology and evolution · 2021
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes ofProceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  16. Article
  17. Review
  18. Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.American journal of respiratory and critical care medicine · 2017
    Article
  19. Review
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daniel E RozenDepartment of Biology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA. daniel.rozen@manchester.ac.uk
Lesley McGee
Bruce R Levin
Keith P Klugman

Funding

Theoretical and experimental strudy of the population and evolutionary dynamics oR01GM091875 · NIGMS · EMORY UNIVERSITY · PI LEVIN, BRUCE RICHARD · 2009 to 2017
$2.5M
NIGMS NIH HHS R01 GM091875
6 · The paper itself

Abstract

The fitness cost of the genes responsible for resistance to fluoroquinolones in clinical isolates of Streptococcus pneumoniae were estimated in vitro in a common genetic background. Naturally occurring parC, parE, and gyrA loci containing mutations in the quinolone-resistance-determining regions were introduced by transformation into S. pneumoniae strain R6 individually and in combinations. The fitness of these transformants was estimated by pairwise competition experiments with a common R6 strain. On average, single par and gyr mutants responsible for low-level MIC resistance (first-step resistance) impose a fitness burden of approximately 8%. Some of these mutants engender no measurable cost, while one, a parE mutant, reduces the fitness of these bacteria by more than 40%. Most interestingly, the addition of the second par or gyr mutations required for clinically significant, high-MIC fluoroquinolone resistance does not increase the fitness burden imposed by these single genes and can even reduce it. We discuss the implications of these results for the epidemiology of fluoroquinolone resistance and the evolution of acquired resistance in treated patients.

Indexed as

MutationDNA GyraseDNA Topoisomerase IVDrug Resistance, BacterialFluoroquinolonesHumansMicrobial Sensitivity TestsPneumococcal InfectionsStreptococcus pneumoniaeTransformation, BacterialDNA GyraseDNA Topoisomerase IVFluoroquinolones

Identifiers

PMID17116668
PMCPMC1797730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.